Since early 2025, the HTA clinical assessment of new cancer drugs and Advanced Therapy Medicinal Products (ATMPs) is now conducted centrally. These Joint Clinical Assessments (JCAs) are aiming to streamline HTA efforts across EU Member States and ultimately accelerating patient access to innovative medicines. Read this factsheet to understand what clients should do to to adapt to the new market access pathway in Europe.